{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:31Z","timestamp":1790796931519,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of fremanezumab for migraine prevention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective, single-center, real-world study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Regional tertiary headache center in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Subjects<\/jats:title>\n                  <jats:p>Adult individuals with migraine (n\u2009=\u2009165, male\u2009=\u200917, female\u2009=\u2009148; average age\u2009=\u200945.5\u2009\u00b1\u200916.0\u2009years) who received fremanezumab between September 2021 and August 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Fremanezumab was administered subcutaneously at a monthly dose of 225\u2009mg or quarterly dose of 675\u2009mg based on patient preferences. Patients received fremanezumab treatment for up to 1\u2009year unless it was discontinued. Monthly data were collected on migraine days, headache days, and days requiring acute medication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 165 patients, 125 (75.7%) received fremanezumab as their first anti-calcitonin gene-related peptide-related antibody drug. Significant reductions in monthly migraine days, headache days, and days requiring acute medication were observed in those with episodic and chronic migraines. The baseline monthly headache days was 8.1\u2009\u00b1\u20094.0 in the episodic migraine group, which reduced to 6.1\u2009\u00b1\u20094.8, 5.8\u2009\u00b1\u20094.4, 4.7\u2009\u00b1\u20093.6, and 4.6\u2009\u00b1\u20093.3\u2009days at 1, 3, 6, and 12\u2009months, respectively; in the chronic migraine group, the baseline monthly headache days was 20.9\u2009\u00b1\u20096.1, which reduced to 17.0\u2009\u00b1\u20098.9, 15.0\u2009\u00b1\u20099.2, 13.0\u2009\u00b1\u20097.7, and 12.0\u2009\u00b1\u20099.1\u2009days at 1, 3, 6, and 12\u2009months, respectively. Treatment benefits were enhanced after 6\u2009months of administering fremanezumab in the chronic migraine group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this real-world study of patients with migraine, fremanezumab appears to be effective and safe. Further studies are required to identify additional predictors of treatment success and failure with fremanezumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnae050","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T18:24:39Z","timestamp":1718735079000},"page":"664-670","source":"Crossref","is-referenced-by-count":12,"title":["Effectiveness of fremanezumab treatment in patients with migraine headache"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0648-0378","authenticated-orcid":false,"given":"Shoji","family":"Kikui","sequence":"first","affiliation":[{"name":"Department of Neurology & Headache Center, Tominaga Hospital , Osaka City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danno","family":"Daisuke","sequence":"additional","affiliation":[{"name":"Department of Neurology & Headache Center, Tominaga Hospital , Osaka City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Miyahara","sequence":"additional","affiliation":[{"name":"Department of Neurology & Headache Center, Tominaga Hospital , Osaka City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanako","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Neurology & Headache Center, Tominaga Hospital , Osaka City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Neurology & Headache Center, Tominaga Hospital , Osaka City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Murakata","sequence":"additional","affiliation":[{"name":"Department of Neurology & Headache Center, Tominaga Hospital , Osaka City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kashiwaya","sequence":"additional","affiliation":[{"name":"Department of Neurology & Headache Center, Tominaga Hospital , Osaka City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Neurology & Headache Center, Tominaga Hospital , Osaka City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"issue":"11","key":"2024110408464668500_pnae050-B1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"2024110408464668500_pnae050-B2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","article-title":"Prevalence of migraine in Japan: a nationwide survey","volume":"17","author":"Sakai","year":"1997","journal-title":"Cephalalgia"},{"issue":"3","key":"2024110408464668500_pnae050-B3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0333102418779544","article-title":"Discovery of CGRP in relation to migraine","volume":"39","author":"Edvinsson","year":"2019","journal-title":"Cephalalgia"},{"issue":"3","key":"2024110408464668500_pnae050-B4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11916-015-0476-1","article-title":"TEV-48125: a review of monoclonal CGRP antibodies for the preventive treatment of migraine","volume":"19","author":"Walter","year":"2015","journal-title":"Curr Pain Headache Rep"},{"issue":"11","key":"2024110408464668500_pnae050-B5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study","volume":"14","author":"Bigal","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1","key":"2024110408464668500_pnae050-B6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/WNL.0000000000002801","article-title":"TEV-48125 For the preventive treatment of chronic migraine: efficacy at early time points","volume":"87","author":"Bigal","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"2024110408464668500_pnae050-B7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicenter, randomized, double-blind, placebo-controlled, phase 2b study","volume":"14","author":"Bigal","year":"2015","journal-title":"Lancet Neurol"},{"issue":"10203","key":"2024110408464668500_pnae050-B8","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"2024110408464668500_pnae050-B9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0333102418772585","article-title":"Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: post-hoc analyses from phase 2 trials","volume":"39","author":"Halker Singh","year":"2019","journal-title":"Cephalalgia"},{"issue":"22","key":"2024110408464668500_pnae050-B10","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2024110408464668500_pnae050-B11","first-page":"e1152","article-title":"Fremanezumab for preventive treatment of migraine: Functional status on headache-free days","volume":"91","author":"Vander Pluym","year":"2018","journal-title":"Neurology"},{"issue":"19","key":"2024110408464668500_pnae050-B12","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"18","key":"2024110408464668500_pnae050-B13","doi-asserted-by":"crossref","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"2024110408464668500_pnae050-B14","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/head.14169","article-title":"Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"issue":"7","key":"2024110408464668500_pnae050-B15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/head.14178","article-title":"Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel group trial in Japanese and Korean patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"key":"2024110408464668500_pnae050-B16","author":"Ministry of Health, Labour and Welfare","year":"2021"},{"issue":"2","key":"2024110408464668500_pnae050-B17","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","article-title":"Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019","volume":"163","author":"Safiri","year":"2022","journal-title":"Pain"},{"key":"2024110408464668500_pnae050-B18","doi-asserted-by":"crossref","first-page":"1169795","DOI":"10.3389\/fneur.2023.1169795","article-title":"Migraine triggers in Asian countries: a narrative review","volume":"14","author":"Iba","year":"2023","journal-title":"Front Neurol"},{"issue":"5","key":"2024110408464668500_pnae050-B19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/ncn3.12322","article-title":"Clinical practice guideline for chronic headache 2013","volume":"7","author":"Araki","year":"2019","journal-title":"Neurol Clin Neurosc"},{"issue":"1","key":"2024110408464668500_pnae050-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"key":"2024110408464668500_pnae050-B21","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2147\/JPR.S329280","article-title":"Central sensitization in migraine: a narrative review","volume":"15","author":"Suzuki","year":"2022","journal-title":"J Pain Res"},{"issue":"1","key":"2024110408464668500_pnae050-B22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s10194-022-01438-4","article-title":"Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies","volume":"23","author":"McAllister","year":"2022","journal-title":"J Headache Pain"},{"issue":"2","key":"2024110408464668500_pnae050-B23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","article-title":"Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score","volume":"36","author":"Iannone","year":"2022","journal-title":"CNS Drugs"},{"issue":"1","key":"2024110408464668500_pnae050-B24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s10194-021-01323-6","article-title":"CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience","volume":"22","author":"Scheffler","year":"2021","journal-title":"J Headache Pain"},{"issue":"1","key":"2024110408464668500_pnae050-B25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","article-title":"Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients","volume":"24","author":"Mu\u00f1oz-Vendrell","year":"2023","journal-title":"J Headache Pain"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnae050\/58362548\/pnae050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/25\/11\/664\/60348799\/pnae050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/25\/11\/664\/60348799\/pnae050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:46:58Z","timestamp":1730710018000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/25\/11\/664\/7695888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6,18]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnae050","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,6,18]]}}}